Balchem Corporation (NASDAQ:BCPC) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On February28, 2019, Balchem Corporation, reported earnings for its fourth quarter ended December 31, 2018, and certain other information. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1.
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
BALCHEM CORP Exhibit
EX-99.1 2 exhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Human Nutrition & HealthAnimal Nutrition & HealthSpecialty ProductsIndustrial Products Balchem Corporation Reports Strong Finish to 2018 with Fourth Quarter Sales of $163.5 million,…
To view the full exhibit click here
About Balchem Corporation (NASDAQ:BCPC)
Balchem Corporation (Balchem) is engaged in the development, manufacture, distribution and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical and medical sterilization industries. The Company operates in four segments: SensoryEffects, Animal Nutrition & Health (ANH), Specialty Products and Industrial Products. Its SensoryEffects segment provides creamer systems, dairy replacers, powdered fats, nutritional beverage bases, beverages, juice and dairy bases, chocolate systems, ice cream bases and variegates, grain-based snacks and cereal-based ingredients. ANH segment provides basic choline chloride, and microencapsulation and chelation technologies-based nutritional products. Specialty Products segment provides ethylene oxide and propylene oxide products. Its Industrial Products segment provides Choline Chloride and methylamines. The Company sells its products through its own sales force, independent distributors and sales agents.
